Dementia epidemiology in Hungary based on data from neurological and psychiatric specialty services

Balázs, Nóra; Ajtay, András; Oberfrank, Ferenc; Bereczki, Dániel; Kovács, Tibor

doi:10.1038/s41598-021-89179-3

Cited by 7 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multivariate analysis confirmed that ChEi-filling was an independent significant predictor, even after data were adjusted to age and gender as well. In Hungary, the median survival of patients with all dementias was 3.01 years [ 9 ]; in comparison, ChEi-non-fillers had 2.50 years, while in case of ChEi-fillers it was more than 4 years. There was no significant difference in the length of survival between only ChEi and ChEi plus memantine users, but detailed analysis of memantine use was not the aim of our present study.…”

Section: Discussionmentioning

confidence: 99%

“…The selection of patients and definitions of dementias were the same as in our previous study [ 9 ]. The process is summarized on Fig.…”

Section: Methodsmentioning

confidence: 99%

“…Patients receiving dementia diagnoses before 2013 were excluded. The validation of the database was performed as described previously [ 9 ]: records of patients were compared in NEUROHUN and the local integrated hospital healthcare information technology system (MedSol, T-System, Hungary) of Semmelweis University, Budapest, in a selected period (October 2013) and medical records were reviewed to ensure that the clinical findings support the diagnosis of dementia.

Fig.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary

et al. 2021

Self Cite

View full text Add to dashboard Cite

Dementia is one of the leading causes of death and disability in older population. Previous reports have shown that antidementia medications are associated with longer survival; nonetheless, the prevalence of their use and the compliance with them are quite different worldwide. There is hardly any available information about the pharmacoepidemiology of these drugs in the Eastern-European region; we aimed to analyze the use of cholinesterase inhibitors (ChEis) for the treatment of dementia to provide real-life information from the Eastern European region. All medical and medication prescription reports of the in- and outpatient specialist services collected in the NEUROHUN database in Hungary were analyzed between 2013 and 2016. Survival, adherence, and persistence values were calculated. 8803 patients were treated with ChEis during the study period, which was only 14.5% of the diagnosed demented patients. The survival of treated patients (more than 4 years) was significantly longer than patients without ChEi treatment (2.50 years). The best compliance was observed with rivastigmine patch. Choosing the appropriate medication as soon as possible after the dementia diagnosis may lead to increased life expectancy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The selection of patients and definitions of dementias were the same as in our previous study [ 9 ]. The process is summarized on Fig.…”

Section: Methodsmentioning

confidence: 99%

Fig.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Concerning the epidemiology of the disease, conclusions were primarily drawn from coding and literature data. [17,18] Although there were post-mortem studies that found that the proportion of people suffering from vascular dementia in the Hungarian sample was significantly higher than the international rate. [19] Perhaps it is also due to this Hungarian peculiarity that, according to general practitioners, the most common form in Hungary is the vascular type of dementia, and they are not far from the truth with this belief, and perhaps that is why an officially recommended screening protocol is only available for this type, but of course, it can also be the cause of the distorted opinion of general practitioners.…”

Section: Introductionmentioning

confidence: 99%

Applicability of the Hungarian Version of the Test Your Memory in General Practice for Screening Mild Cognitive Impairment and Early Stage Dementia

Garbóczy¹,

Mohos²,

Égerházi³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: dementia is a significant health issue worldwide. Mild cognitive impairment (MCI) can transform into dementia over time. General practitioners may be the first to notice the cognitive deficit, so they may need a screening test in the event of suspicion, which they must be able to use under great time pressure. We examined the usability of the Hungarian Test Your Memory (TYM-Hun) self-administered dementia test in general practice, and with the results of the received tests, we tried to draw conclusions regarding the population. Methods: In the four Hungarian cities with medical universities, general practitioners filled out 368 questionnaires with their clients over 50 years of age. Results: the total scores of the test showed a significant correlation with education and the type of occupation, while a significant negative correlation with age. We found the clock drawing test and recall indicates cognitive decline the earliest. Based on the TYM-Hun results, the prevalence levels for MCI and dementia are slightly higher in Hungary than globally. Conclusion: the test can sensitively indicate MCI and early-stage dementia as a screening test, and two of its subtests can raise the possibility of cognitive impairment at an earlier age than the others.

show abstract

“…Approximately 50 million people suffer from dementia. This number is expected to triple by 2050 [ 1 , 2 , 3 ]. When dementia develops, it primarily affects memory and other cognitive functions, making daily life activities challenging and affecting orientation in time and space and speech [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Suicide-Related Single Nucleotide Polymorphisms, rs4918918 and rs10903034: Association with Dementia in Older Adults

Abramova

Solovevа²,

Zorkina

et al. 2022

Genes

View full text Add to dashboard Cite

Dementia has enormous implications for patients and the health care system. Genetic markers are promising for detecting the risk of cognitive impairment. We hypothesized that genetic variants associated with suicide risk might significantly increase the risk of cognitive decline because suicide in older adults is often a consequence of cognitive impairment. We investigated several single-nucleotide polymorphisms that were initially associated with suicide risk in dementia older adults and identified the APOE gene alleles. The study was performed with subjects over the age of 65: 112 patients with dementia and 146 healthy volunteers. The MMSE score was used to assess cognitive functions. Study participants were genotyped using real-time PCR (APOE: rs429358, rs7412; genes associated with suicide: rs9475195, rs7982251, rs2834789, rs358592, rs4918918, rs3781878, rs10903034, rs165774, rs16841143, rs11833579 rs10898553, rs7296262, rs3806263, and rs2462021). Genotype analysis revealed the significance of APOEε4, APOEε2, and rs4918918 (SORBS1) when comparing dementia and healthy control groups. The association of APOEε4, APOEε2, and rs10903034 (IFNLR1) with the overall MMSE score was indicated. The study found an association with dementia of rs4918918 (SORBS1) and rs10903034 (IFNLR1) previously associated with suicide and confirmed the association of APOEε4 and APOEε2 with dementia.

show abstract

Dementia epidemiology in Hungary based on data from neurological and psychiatric specialty services

Cited by 7 publications

References 28 publications

Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary

Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary

Applicability of the Hungarian Version of the Test Your Memory in General Practice for Screening Mild Cognitive Impairment and Early Stage Dementia

Suicide-Related Single Nucleotide Polymorphisms, rs4918918 and rs10903034: Association with Dementia in Older Adults

Contact Info

Product

Resources

About